Tanja Obradovic: A novel mechanism for first-line melanoma patients is going to be explored by Eikon Therapeutics
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Since December 2015 when it received FDA approval for the first-line treatment of unresectable or metastatic melanoma, Keytruda (Pembrolizumab) provides important standard of care.
However, more than 50% of first-line melanoma patients do not respond to PD-1 inhibition resulting in combination therapy investigations. Important updates in this area is ongoing with novel mechanism to be explored by very innovative Biotech Eikon Therapeutics.
Eikon Therapeutics announced very successful $350.7 million in Series D financing, one of the largest executed by Biotechs this year. Based on clinicaltrial.gov update Phase 2/3 Study comparing EIK1001 and Pembrolizumab combo versus placebo and Pembrolizumab as first-line treatment in patients with advanced melanoma is to be enrolling as of this month (NCT06697301).
EIK1001 is a dual agonist of Toll-like Receptor 7 and 8 (TLR7 and TLR8) that stimulates myeloid and plasmacytoid dendritic cells.
Stimulation of both TLR7-mediated innate immunity and TLR8-mediated adaptive immunity opens both pathways as alternatives to signaling via checkpoint proteins enabling possibility for enhanced antitumor T-cell activity alone or in combination with checkpoint inhibitors.
TLR are a large family of receptors and numerous drugs targeting this family are in the clinical development for various malignancies so definitively good news for cancer patients despite challenging financing times Biotech is currently facing.”
More posts featuring Tanja Obradovic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023